Cleveland State University

EngagedScholarship@CSU
ETD Archive

2018

Quantitative Analysis of Bleomycin in Rat Plasma
by LC-MS/MS
Huawen Li
Cleveland State University

Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Analytical Chemistry Commons, Biochemistry Commons, and the Other Chemistry
Commons
How does access to this work benefit you? Let us know!
Recommended Citation
Li, Huawen, "Quantitative Analysis of Bleomycin in Rat Plasma by LC-MS/MS" (2018). ETD Archive. 1036.
https://engagedscholarship.csuohio.edu/etdarchive/1036

This Thesis is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

QUANTITATIVE ANALYSIS OF BLEOMYCIN IN RAT PLASMA BY LC-MS/MS

HUAWEN LI

Bachelor of Science in Chemistry
Cleveland State University
May 2015

Submitted in partial fulfillment of requirements for the degree
MASTER OF SCIENCE IN CHEMISTRY
at the
CLEVELAND STATE UNIVERSITY
MAY 2018

We hereby approve this thesis for
HUAWEN LI
Candidate for the Master of Science in Chemistry degree for the
Department of Chemistry
and the CLEVELAND STATE UNIVERSITY’S
College of Graduate Studies by

Committee Chairperson, Dr. Baochuan Guo

Department & Date

Committee Member, Dr. David Anderson

Department & Date

Committee Member, Dr. Bin Su

Department & Date

Student’s Date of Defense:

04-27-2018

ACKNOWLEDGMENT

Firstly, I would like to thank my family for their understanding and supporting my
studies. My parents, Ze Li and Lixia Han, have filled my life with their love and have
supported me financially, which has encouraged me to achieve my goals. My aunt, Dr.
Yingchun Han, has been a big influence on my life in the United States and has guided
me in pursuing my studies in the field of science. She has inspired me by her ways and
she has shown me how avoid difficulties to make my life much easier and enjoyable. She
also introduced me a research lab at the Cleveland Clinic Lerner Research Institute, from
which a technician generously donated the analyte standards and rat plasma samples for
my research study. I thank them tremendously for their support.
I would like to express my deepest gratitude to my thesis supervisor, Dr.
Baochuan Guo, of the department of chemistry at Cleveland State University. Under his
guidance I gained extensive knowledge of liquid chromatography and mass spectrometry.
Thanks is also owed to Dr. Xiang Zhou, who has provided training for all the analytical
instrumentation and has instilled in me critical thinking skills as well as tips on
troubleshooting and other technical abilities. Their guidance, assistance, and
encouragement has all helped me through this journey of completing my master thesis.
My good friends and lab partners, Dr. Ravali Alagandula and PhD candidate
Gang Xu from Dr. Yan Xu’s lab, have helped develop my research and always pitched in
with their experienced ideas and expertise, without whom, I would not have been able to
have achieved the profound results of this project. I thank them for all for their help and
patience.

I would also like to graciously thank Dr. Bin Su and Dr. David Anderson who
took the time to participate in my final defense committee, providing valued and
appreciated advise, which has markedly improved this work.

QUANTITATIVE ANALYSIS OF BLEOMYCIN IN RATS PLASMA
WITH LC-MS/MS
HUAWEN LI
ABSTRACT
Bleomycin is the most commonly used compound in its group of antineoplastic
drugs. It works on tumor cells by single and double stranded DNA cleavage after its
activation, in which it blocks tumor cells’ DNA replication or transcription activities to
inhibit tumor cells’ growth. Bleomycin sulfate (Blenoxane) is the most popular
preparation used in clinical research, and contains Bleomycin fractions of A2 and B2,
which causes difficulties in quantitative analysis. This work uses the metal chelating
property of Bleomycin as an advantage to simplify and improve sensitivity of existing
quantitative methods.
Copper was spiked in excess to plasma samples, followed by liquid-liquid
extraction. Samples were then subjected to analysis by high-performance liquid
chromatography electrospray ionization tandem mass spectrometry using a quadrupole
trap mass analyzer. Samples spiked with copper showed improved selectivity over
samples without excess copper, thereby making use of standard mass spectrometers a
possibility in the clinic. In comparison with current methods of quantification of
Bleomycin in plasma, this method achieved higher percent recoveries of the
chemotherapy drug, higher sensitivity of quantification, with lower matrix effects, as well
as a more simple preparation method. Linear range in the lower nanogram per milliliter
range with a correlation coefficient over 0.99 makes this method promising for improved
quantification and monitoring of Bleomycin in plasma.
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CHAPTER I
INTRODUCTION
1.1 Blenoxane
Bleomycin sulfate (Blenoxane; BLM; DB00290; Fig. 1)3 is a widely used drug in
oncology used to treat a variety of cancers, such as Hodgkin’s and non-Hodgkin’s
lymphoma, testicular cancer, ovarian cancer, and cervical cancer among others.1 BLM is
also used as a highly effective cytostatic antibiotic. In its use as an anticancer agent, BLM
can be given intravenously by injection into the muscle or under the skin.1 The advantage
of the BLM compared to other chemotherapeutic drugs and other drugs in its class
includes use in multi-cancer therapy, fewer side effects, and that it is not damaging to the
bone marrow and the immune system.1, 2, 3 Bleomycin was discovered in 1962, and the
most widely used drug is isolated from the fermentation broth of Streptomyces verticillus.
Current clinically administered preparations of the drug mixture has more complex
contents. The most common Bleomycin drug is the Bleomycin sulfate (Blenoxane),
which mainly consists of metal (Cu) ions, 55-70% of Bleomycin A2 [molecular weight
(M.W.) of 1414.52], and 25-32% of Bleomycin B2 (molecular weight of 1424.56).2,3 The
rationalization as to when bleomycin sulfate is used as a treatment in clinical use is with a
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deep consideration of its toxicity; therefore the research on its side effect from hydrolysis
studies is an interest of some research groups.

Figure 1. The chemical structure of bleomycin sulfate. IUPAC name: {(3-{[2-(2-{2[(2S,3R)-2-[(2S,3S,4R)-4-[(2S,3R)-2-({6-amino-2-[( 1S)-1-{[(2S)-2-amino-2carbamoylethyl]amino}-2-carbamoylethyl]-5-methylpyrimidin-4-yl}formamido)-3-[(3{[4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6(hydroxymethyl)oxan-2-yl)oxy]-3-(1H-imidazol-5-yl)propanamido]-3-hydroxy-2methylpentanamido]-3-hydroxybutanamido]ethyl}-1,3-thiazol-4-yl)-1,3-thiazol-4yl]form-amido}propyl)dimethylsulfanium}.3,4

1.2 Overview of Research on Bleomycin
It is important to understand the mechanism and metabolism of Bleomycin, not
only for its biochemical mechanism of DNA damage knowledge but also to be able to
accurately quantify this significant anticancer drug for clinical use. The most commonly
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used Bleomycin sulfate preparation contains two main fractions, as well as chelating
copper (II) ions. A clearly understood mechanism and metabolic pathway facilitates the
generation and development of clinically relevant treatments and diagnostic
methodologies, for example the production of agonists and antagonists that reduce harm
to patients from its side effects and moreover analytical methods can also be developed to
improve quantification, diagnosis, and therapeutic monitoring all more accurately and
precisely.
Bleomycin, a glycoprotein, that is comprised of two sugar rings and a polypeptide
chain if four amino acids in length (Fig. 2). Five amino groups confer the molecule’s high
polarity. It is documented that the anticancer properties of Bleomycin must be activated
by incorporation with metal ions and free molecular oxygen.6 Bleomycin can be activated
by a metal binding ions and oxygen molecules enabling it to react with double stranded
DNA, specifically with deoxyguanosine-phosphate-deoxycytosine (GpC) and
deoxyguanosine-phosphate-thymidine (GpT) residues, which then produces a
pseudoenzyme and hydroxide free radicals, thereby cleaving both strands of DNA.
Bleomycin hydrolase is the only enzyme that is known to metabolize Bleomycin on its αamino-carboxylamide group. Bleomycin hydrolase is a cytosolic cysteine proteinase
enzyme that is widely distributed in normal tissues except for the skin and lungs, in
which case, targets of Bleomycin toxicity cause extreme side effects.

3

Figure 2. The structural contents of bleomycin sulfate.5 Bleomycin hydrolase converts
Bleomycin to desamido-bleomycin, which presents as its fifth coordinate nitrogen is
replaced by a carboxyl group, decreasing the oxygen activating affinity of the
Bleomycin-Fe(II) complex resulting in the loss of Bleomycin’s activity. In this case,
bleomycin’s 5’-amine might be the key to control the activity of Bleomycin.

1.3 Mechanism of Action
Bleomycin is a structurally complex compound containing distinct regions that
participate in the compound’s biological activity. Bleomycin sulfate structure is divided
into three domains: Metal-binding domain, two sugar moieties, and DNA binding
domain. The metal-binding domain binds a metal ion and an oxygen molecule to activate
bleomycin. The sugar moieties facilitate uptake into the cellular membrane for drug
delivery. And lastly, the DNA binding domain, a bithiazole, specifically identifies and
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binds to deoxyguanosine at the minor groove of both single- and double-stranded DNA,
which is the precursor step to cleave DNA strands.
1.3.1 Metal-Binding Domain
In the metal-binding domain, only the deprotonated amide nitrogen binds to the
metal biding site.5 The metal-binding domain can bind a variety of metal ions, however
Cu(II) has the highest coordinate affinity and BLM is most often found as a complex with
Cu(II). Once the activated bleomycin that binds with Cu(II) is transported into the cells,
Cu(II) is converted into Cu(I) by intracellular reductants and then is unbounded from
BLM-Cu complex and is converted back to free BLM (Fig. 3).6 Intracellular Fe(II) binds
to BLM on its metal-binding domain at the deprotonated amide nitrogen sites, then the
complex is oxidized to BLM-Fe(III)-OOH-, thereby releasing hydroxide free radicals that
cleave DNA. BLM-Fe(III) is then converted to BLM-Fe(II) by intracellular reductants as
NADH, ascorbic acid, or 2-hydroxy-1-ethanethiol (Fig. 4).7,8
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Figure 3. The pathway of bleomycin transportation into the cell and its metal-binding
condition. Bleomycin sulfate binds to Cu(II) as an extracellular activation to be
transported into the cell. Cu(II) ion is unbound in the cell, and bleomycin then binds to
the Fe(II), and then to be oxidized to a BLM-Fe(III)-OOH- to release hydroxide free
radicals to catalyzing DNA cleavage in the cell nucleus.6,7,8

Figure 4. Hypothesis of catalyzing BLM-Fe(II) complex by oxygen.8
6

1.3.2 Sugar
Glucose and mannose form a disaccharide structure that does not directly bind to
the DNA. This structure’s purpose is to stabilize the BLM-Fe complex, and enhance the
drug’s uptake into the biological membrane.
1.3.3 DNA Binding Domain
The DNA binding domain is a bithiazole structure, which is the main structure
that binds to the DNA. The bithiazole preferentially identifies the Guanine nucleobase of
DNA.8 Bithiazole has properties of aromaticity and coplanarity. Since it identifies
Guanine of the DNA, it inserts specifically between both single or double strand
deoxyguanosine-phosphate-deoxycytosine and deoxyguanosine-phosphate-thymidine at
the minor groove to make an interlayer complex.9 BLM-Fe-OO extracts a hydrogen atom
from the 4’ carbon of the guanosine-connecting deoxyribose then reacts with the oxygen
free radical to break the chain.9 The identification of products indicates that there are two
pathways that activate BLM-Fe to induce the mechanism of DNA cleavage. When there
is excess of oxygen, the 4’ carbon hydroperoxide intermediate is produced as basepropenal to break the deoxyribose.8 In a hypoxic enviornment, the dissociative base can
be detected. The bond between 3’-phosphate and 3’ carbon of deoxyribose breaks to
cleave the chain, and oxygen on the deoxyribose breaks with 4’ carbon to produce the
dissociated base radical (Fig. 5).8
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Figure 5. Two pathways that BLM-Fe(II)-O2 catalyzes DNA cleaverage.8

1.4 Metabolism
The metabolism and distribution of BLM hydrolase in an organism’s body is the
main cause of some adverse side effects including conditions of the lung, fibrosis and
rash development. To reduce the side effects, current research groups are investigating
the hydrolysis pathway of Bleomycin and toxic effect dosage by employing analytical
techniques such as chromatography and spectroscopy with statistical analyses to gain
information on target molecule distribution on organs and toxicity.
Bleomycin hydrolase is the only enzyme that inactivates bleomycin. Bleomycin
hydrolase is a group of cytosolic cysteine proteinase enzymes that are widely distributed
in normal tissue with the exception of the skin and lungs, which causes extremely toxic
side effects in these areas which include fibrosis of the lung tissue and rashes.3 BLM
hydrolase metabolizes BLM on its α-amino-carboxylamide to loose and amide to produce
product as desamido-bleomycin (desBLM). In desBLM, Fe(II) ion binds to the carboxyl
group instead of a nitrogen, thereby decreasing the oxygen activating affinity of this

8

desBLM-Fe(II) complex, in which case desBLM-Fe(II) complex weakens or loses its
ability to release oxygen free radicals to fail on DNA cleavage.

Figure 6. Change of metal-binding site of desamido-bleomycin. BLM hydrolase
metabolizes BLM on its α-amino-carboxylamide. Desamido-bleomycin then changes its
metal-binding site into the carboxyl group instead of nitrogen, thereby decreasing the
oxygen activating affinity of this desBLM-Fe(II) complex.

1.5 Consideration of Bleomycin Quantitative Analysis
Most assays for the quantification of Bleomycin employ techniques with poor
sensitivity such as ultraviolet or fluorescent detection or radioimmuno-assays. Current
quantification mostly uses liquid chromatography (LC) with fluorescence or ultraviolet
(UV) detection. Detector of UV is limited to where saturated organic compound
transitions occur. Also, only π-π and p-π conjugated unsaturated esters absorb in the near
UV band. The first group to publish a method for the analysis of Bleomycin by HPLC
was Shiu and Goehl10 in 1980 followed by Mahdadi et al.11 a decade later who published
a more sensitive method with a fluorescence detector and ion-paring reverse phase HPLC.
These two methods were only validated for the A2 fraction and in addition only achieved
a sensitivity of 70 nanograms per milliliter, which is not sufficient for detection in human
plasma. In 2012 Mabeta et al.12 developed a HPLC method for separation and
quantification of both A2 and B2 fractions, however this method had several weaknesses,
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in that it had a narrow linear range and the actual BLM concentration would exceed their
upper limit of quantification.
Mass spectrometry is able to overcome these limitations of other detection
methods and is unparalleled in the quantification of small molecule metabolites. Tandem
mass spectrometry ensures confidence in quantification and the highest selectivity. The
biggest advantage in using MS/MS is no need to consider about separating impurities.
The dosage of Blenoxane is about 0.25-0.50 units/kg, and it would reach peak plasma
concentration (1-3ug/mL) in 30-60 minutes. The terminal half-life is approximately 3
hours, and about 65% of administered intravenous dosage is excreted in urine within 24
hours. MRM channel has enough sensitivity (pg/mL) to quantify such low level of
concentration.
Although several research groups have developed LC-MS methods to determine
the concentration of BLM in plasma samples, these methods have low selectivity and
would present a problem in the presence of analytes of similar structure. More successful
methods such as Galba et al.13 and Kosjeck et al.14 rely on high resolution mass analyzers
(Q-TOF; quadrupole-time-of-flight) to elucidate quantitative peaks in a complex spectra
of many isotopic patterns. Such instruments are not readily available nor widespread in
the clinical setting. The methods mentioned also require time consuming sample
preparation steps or uncommon chromatography conditions, making the methods
impractical. Since there does not exist a simple and accessible method for the
quantification of Bleomycin in plasma, development of such method is in need as the
ability to quantify the chemotherapeutic drug in plasma is important in determining the
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therapeutic window of the drug as well as toxicity in addition to monitoring the efficacy
of therapy.
1.6 Aims and Objectives
The objective of this project is to design a method to quantify BLM-Cu complex
in plasma, overcoming its low concentration and multiple formations. The purpose of
analyzing activated BLM is for its clinical utility and it is thus important to convert all
BLM into BLM- Cu2+ complex. As same molecular weight with desBLM and BLM, the
targets on BLM-Cu2+ complex would also eliminate the interference of desBLM to the
final quantitation of BLM.
Specifically the methods developed aims to reduce the interference and instability
of BLM and increase the sensitivity by transferring all non-metal binding BLM into
metal binding BLM. The second aim is to utilize widely-available LC-MS
instrumentation that is translatable to the clinical setting, therefore the method was
developed using LC-ESI-triple-quadruple mass spectrometer with appropriate conditions.
1.7 Method Development
This method was developed to utilize a quick and efficient extraction technique,
liquid-liquid extraction, in order to reduce effect matrix, and improve sensitivity of LCMS/MS detection, which realizes high sensitivity, high selectivity, and reduced loss of
analyte in the process of the analysis. The cost of mass spectrometer is high; however, it
satisfies the highest sensitivity and selectivity of the analysis with its MRM channel. The
solvent buffer and mobile phases does not contain complex contents, which is easily
prepared and remained stable. To extract analytes from the plasma samples, only simplest
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protein precipitation by using high concentration of methanol would satisfy high recovery
of the analysis.
1.7.1 Liquid-Liquid Extraction
BLM is highly polar and easily dissolved in water and methanol, and there is no
effect with the proteins in plasma. In this method, 70% and higher concentration of
methanol is prepared for protein precipitation. After ice-dry evaporation and
concentration with 20% methanol, the working solutions would remain ＞95% of the
original spiked BLM. In comparison with solid-phase extraction, liquid-liquid extraction
saves solid-phase column and complicated extraction procedures.
1.7.2 Mass Spectrometry
Mass spectrometry provides qualitative and quantitative information about the
atomic and molecular composition of inorganic and organic materials. The mass
spectrometer produces charged particles that consist of the parent ion and ionic fragments
of the original molecules. The mass analyzer then sorts these ions according to their
mass/charge ratio. The mass spectrum is a record of the relative numbers of different
kinds of ions and is characteristic of every compound, including isomers. In tandem
quadrupole MS, collision induced dissociation in the second quadrupole cell, Q2, and
selection of fragments of parent ion in the ion trap is advantageous in the quantitative
analysis of compound in solvent.
Electrospray ionization (ESI) is a soft ionization technique that produces ions
using an electrospray in which a high voltage is applied to a liquid to create an aerosol.
As use of MALDI, ESI is especially useful to produce ions from macromolecules because
it overcomes the propensity of these molecules to fragment when ionized. A solution of
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macromolecules is sprayed in the form of fine droplets from a glass capillary under the
influence of a strong electrical field. The droplets pick up charge as they exit the
capillary, and the evaporation of the solvent leaves highly charged molecules. Since
droplets “break down” to form spray and evaporate, the charge increases many times
until the gas-phase molecules or fragments finally enter the analyzer. The ESI is mostly
used to analyze thermo-instable polar macromolecules, and the sample molecules hardly
disintegrate during the ionization. Slower flow rate causes more fragments via ionization,
furthermore contributing to the high degree of sensitivity. However, ESI limits the
molecular structures, which easily cause thermo-dissociation. The chemical noise
presents clearly since the molecular mass is low. It is also not suitable for large M.W.
molecules which larger than 1000Da, but this can be fixable by changing flow rate. The
molecular weight limit is too small for Bleomycin which averages as ~1414Da. However
this is overcome by the ability of ESI to form multiple charges. At +2 charges channel,
that has satisfied the molecular weight limit and the drug can be detected in the spectrum
although the spectrum does not show the singly charged compound.
1.7.3 High-Performance Liquid Chromatography (HPLC)
HPLC is widely used to separate mixed compounds based on their polarities.
HPLC consists of liquid mobile phases and a stationary phase that can be reused. It uses
high pressure to ensure the mobile phase quickly passes through the stationary phase
packed in the column. It has a quicker flow rate and more rapid analysis than traditional
liquid chromatography. It is highly effective and highly sensitive to analyze low
concentration of analytes (0.01 ng).
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The mostly commonly used stationary phase in HPLC is reverse phase columns,
which strongly retain polar compounds on the column and eluted with reversed polarity
of mobile phases to realize high selectivity. In combination with tandem quadrupole MS,
the LC-MS/MS system delivers the highest selectivity of separating compounds from
complex biological matrices and with little to no interference from compounds of the
same molecular weight as the target analytes. In this method, the column specially used is
a SYNERGITM HYDRO-RP Polar Endcapped C18 Column (Fig. 7), which specializes in
the application for extreme retention of non-polar and extremely polar alkyl compounds.
The mobile phase A is 20mM of ammonium formate and 0.1% of formic acid and mobile
phase B is 0.1% of formic acid in 100% of methanol. The elution appears to be polar with
time gradients of 20-60% of mobile phase B.

Figure 7. Structure of SYNERGITM HYDRO-RP Polar Endcapped C18 Column. On the
inter-surface of the column, there are C18 and polar site, which presents good retention
on both polar and non-polar compounds.15

14

CHAPTER II
MATERIALS AND METHODS
2.1 Chemicals and Solutions
Blenoxane was purchased from Alexis Biochemicals, in which contains ~67% of
BLM A2 and ~29% of BLM B2. The internal standard Vancomycin hydrochloride (VCM)
was purchased from Sigma Aldrich (St. Louis, MO). Methanol (≥99.9%) and ammonium
formate ((≥99%) were purchased from Sigma Aldrich (St. Louis, MO). Water is purified
using the Millipore Milli-Q system (Milford, MA). Formic acid was purchased from
Fluka.
Mobile phase A is prepared by dissolving ~0.63g of ammonium formate and 1mL
of concentrated formic acid into 1L of DI-water, which is prepared as 20mM of
ammonium formate and 0.1% formic acid. Mobile phase B is prepared as 0.1% formic
acid by dissolving 1mL of formic acid into 1L of 100% methanol.
2.2 Sample Preparation
Two groups of rat plasma were generously provided by a research group at
Cleveland Clinic Lerner Research Institute. In 2012, the lab in Cleveland Clinic Lerner
Research Institute commenced a project that injecting BLM into the lungs and bronchia
of rats, and records the condition of lung fibrosis by timekeeping. Eight rats at an age of
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eight weeks old were injected with 25mg of BLM into lungs and bronchia while the other
six were kept as controls. After 14 or 28 days, plasma samples were collected and
0.5mL/L EDTA was treated. All plasma samples had been kept at -80℃ until obtained at
April 2016. The obtained 50mg of BLM standards were dissolved in DI-Water and stored
in -80 degree in Celsius, which caused a problem of sample degradation for subsequent
stability tests. BLM is a highly polar compound, which has high solubility in water and
methanol, and neither would ensure that it would retain its stability stored in solvent.
2.3 Calibration Curve Standard Preparation
BLM is very toxic and is delivered as a powder, so it is not suggested to prepare
the solutions by weighing. The BLM analyte standard consisted of 50 mg of powder, and
was directly dissolved in 1mL of DI-water. At the temperature of -80℃ for storage, water
is more stable than that in methanol. As high concentration of methanol would need to
precipitate proteins in plasma, further stock solutions would be prepared in 100%
methanol. From the 1mL of 50mg/mL stock solutions, 50μL was vortexed and mixed
with 49.95mL of 100% methanol to prepare a concentration of 50μg/mL secondary stock
solution. From the secondary stock solution, 500μL was vortexed and mixed with
49.5mL of 100% methanol to prepare a concentration of 500ng/mL stock solution. 20mL
from the 500ng/mL stock solution was vortexed and mixed with 30mL of 100% methanol
to prepare a concentration of 200ng/mL stock solution, and from which 5mL was
vortexed and mixed with 45mL of 100% methanol to prepare a concentration of 20ng/mL
stock solution. 500ng/mL, 200ng/mL, and 20ng/mL stock solutions were stored at -20℃
until use.
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0.5 mg of the internal standard VCM was vortexed and mixed with 1mL of 100%
methanol to prepare the 0.5mg/mL main stock VCM solution, and from which 0.5mL
was vortexed and mixed with 49.5mL of methanol to prepare the 5μg/mL secondary
solution. All these stocks were stored at -80℃. 2mL of the 5μg/mL stock was vortexed
and mixed with 48mL of methanol to prepare 200ng/mL of VCM stock, and which was
stored at -20℃ until use.
As checked common bio-clinical treated plasma, there usually is 1.5-1.8mg/mL of
EDTA treated, which is transferred as 4mM. The provided plasma samples were treated
by 0.5M of EDTA. However, only to consider of the chelation between Cu2+ and EDTA
(if there is any) by 1:1 ratio, 4mM of EDTA was prepared by dissolving 75.0mg of
EDTA (molecular weight of 372.24g/mL) in 50mL of DI-water.
2mM of CuSO4·5H2O (molecular weight of 249.677) was prepared by dissolving
25mg of solid CuSO4·5H2O in 50mL of DI-water.
To test selection and sensitivity of the method, the calibration standards were
prepared as the final concentration of BLM from 1ng/mL, 5ng/mL, 10ng/mL, 20ng/mL,
50ng/mL, 100ng/mL, and 200ng/mL. In the test period, plasma was replaced by DI-water
to save the cost of plasma. To ensure the accuracy of concentration prepared, three BLM
stock solutions were used to prepare corresponding standards. Final concentration of
VCM was 40ng/mL. The solvent was prepared as 70% methanol. The calibration curve
standards were prepared as shown in Table I.
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BLM
Stock
conc.
(ng/mL)

Blank
Plasma or
DI-water
(μL)
32

2mM
CuSO4
(μL)

100%
Methanol
(μL)

VCM
(200ng/mL)
(μL)

BLM
(μL)

Double
16
112
Blank
Blank
32
16
80
32
20
1ng/mL
32
16
72
32
8
5ng/mL
32
16
40
32
40
10ng/mL
32
16
0
32
80
200
20ng/mL
32
16
64
32
16
50ng/mL
32
16
40
32
40
100ng/mL
32
16
0
32
80
500
200ng/mL
32
16
16
32
64
20
LQC
32
16
60
32
20
(2.5ng/mL)
200
MQC
32
16
64
32
16
(20ng/mL)
500
LQC
32
16
28.8
32
51.2
(160ng/mL)
Table I. Calibration Curve Standards Preparations. Concentration of 70% methanol was
used to precipitate proteins from plasma. In the future research and method optimization,
each standard would be ice-dried and dissolved in 20% methanol for instrumentation
injection and detection.

2.4 Protein Precipitation
All plasma samples were stored at -80℃ until use. After the working standards
were prepared, they were vortexed for 1 minute, and then centrifuged at 14,000 rpm for
15 minutes. Transferred 140μL of supernatant into vials with inserters and sent to the
HPLC auto sampler for injection.
In the future research of optimization, each unit of supernatant was ice-dried and
dissolved in 40μL of 20% methanol. Under this condition, the contents of standards
preparation were changed. Prepared standards with concentrations of 1ng/mL, 20ng/mL,
50ng/mL, 100ng/mL, and 500ng/mL in 100% methanol. The final methanol
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concentration was changed to 80% to precipitate plasma proteins. The optimized
standards were prepared as shown in Table II.
Blank
2mM CuSO4
100%
VCM
BLM (μL)
Plasma or
(μL)
Methanol
(200ng/mL)
DI-water
(μL)
(μL)
(μL)
1ng/mL
32
16
160
32
2
20ng/mL
32
16
160
32
2
50ng/mL
32
16
160
32
2
200ng/mL
32
16
160
32
2
500ng/mL
32
16
160
32
2
Table II. Optimized Standards Contents. This preparation plan was to optimize the
protein precipitation and tried to higher the sensitivity of the method. However, in case of
BLM stability reduce, it would not be used to make a calibration curve.

2.5 HPLC-MS/MS Instrumentation
The instruments used were a HPLC and tandem quadrupole mass spectrometer
system. The mass spectrometer was 5500 QTRAP triple quadrupole, tandem mass
spectrometer (AB Sciex, Toronto, Canada). The high-performance liquid
chromatography (HPLC, Shimadzu, Columbia, MD, USA) was composed of two LC-30
AD pumps, DUG-20A3R inline degasser, a SIL-30 AC autosampler, a CBM-20A
controller and a CTO-10AVP column oven (Shimdazu, Tokyo, Japan).
2.6 HPLC-MS/MS Optimization Parameters
High-performance liquid chromatographic separation was carried using a Synergi
4μ Hydro-RP 80A (50×2.00mm, 4 micron). The parameters of HPLC and MRM channel
are shown in the Table III, IV, and V below.
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Shimadzu LC System Equilibration Time
Shimadzu LC System Injection Volume
Pump
Pumping Mode
Total Flow Rate
Pump B Concentration
Oven
Temperature
Time Program
0.01 min
2.00 min
9.50 min
9.51 min
10.00 min
Table III. Shimadzu LC System Parameters.

Q1 m/z

10.00 min
5.00 μL
Binary Flow
0.2 mL/min
5%
40℃
Pump B Concentration 20%
Pump B Concentration 50%
Pump B Concentration 60%
Pump B Concentration 2%
Stop

Q3 m/z

Collision
Energy Start
BLM A2
739.0
707.7
40
BLM B2
744.3
551.7
45
VCM
725.9
100.2
47
Table IV. MRM Fragmentation Transition in Positive Ion Mode.

Ion Source
Turbo Spray
Curtain Gas (CUR)
40.0
Collision Gas (CAD)
High
IonSpray Voltage (IS)
4500.0
Temperature (TEM)
650.0
Ion Source Gas 1 (GS1)
31.0
Ion Source Gas 2 (GS2)
31.0
Declustering Potential (DP)
60.0
Entrance Potential (EP)
10.0
Collision Cell Exit Potential (CXP)
13.0
Table V. Optimized Mass Spectrometry Parameters.
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Collision
Energy Stop
40
45
47

CHAPTER III
RESULTS AND DISCUSSIONS
3.1 Method Application
Method validation according to FDA guidelines was not completed for this
method. However, based on the completed method optimization, this method can
quantify at least 0.2ng/mL of analyte concentration in plasma and standard calibrations
curves with a correlation coefficient above 0.99 indicate the method indeed satisfies the
requirements. The sensitivity is improved by solvent buffer optimization to increase
injection volume and a concentration process to satisfy lower concentration analysis. As
the BLM-Cu complex is more active in the mechanism of action, an appropriate amount
of CuSO4 is added to enhance the components of BLM-Cu. One research group published
an HPLC/MS/MS method to quantify Vancomycin, and in which mentioned to consider
about using BLM as internal standards.16 This study used Vancomycin as the internal
standard for BLM quantification successfully. The structure of Vancomycin is a
glycoprotein, in which there are two sugar residues just like BLM. Also there lots of
aromatic rings just like BLM. So the structures are very similar, which makes a good
choice to make as an internal standard.
3.2 Mass Spectrometry Results
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3.2.1 Mass Spectrometry Q1 Infusion – BLM and VCM
In the Blenoxane that was obtained from Alexis Biochemicals, the main
compositions are BLM A2 (67%) and BLM B2 (29%). The other compositions are shown
in Table VI below.
Bleomycin A2
Bleomycin B2
Demethylbleomycin A2
Bleomycin B4
Other Related Substances
Copper
Loss on Drying
Product Description
Table VI. Compositions in Blenoxane.

67%
29%
0.3%
0.03%
3.5%
109ppm
2.5%
Isolated from Streptomyces verticillus

The primary Q1 scan is shown in Figure 8 below.

Figure 8. 1μg/mL BLM in 90% Methanol Q1 Scan. The B2 fraction, which is the more
relevant biological form, in the spectra chelated with spiked excess of Cu(II) reduces the
signal interference as it is almost completely converted to the copper-complex.

The molecular weight of BLM A2 is 1414.52 and BLM B2 is 1424.56. To chelate
with Cu2+, the corresponding molecular weights change to 1478.066 and 1489.206. The
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m/z limit of the Qtrap instrument is 1250, therefore, the BLM A2 and B2 are present as
their m/z of bivalence.
m/z
BLM A2
708.0
BLM B2
713.5
2+
BLM A2 – Cu
739.0
BLM B2 – Cu2+
744.5
Table VII. m/z of Each BLM Fractions in Spectrum with Q1 Channel.
According to the spectrum, there is BLM A2 without chelating with Cu2+, which
explains that BLM B2 has stronger chelation with Cu2+. In the future optimization, excess
of Cu2+ from CuSO4 would be added to the standard preparation to transfer all BLM to
BLM-Cu as much as possible.

Figure 9. 500ng/mL VCM (725.4) in 70% Methanol Q1 Scan.
3.2.2 Mass Spectrometrum Q1 Infusion – BLM and Cu Chelation
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According to the spectrum, BLM A2 has mostly transferred to BLM A2 – Cu
chelation. However, to consider if there is reversible reaction on this chelation, a pair of
comparative Q1 spectrums with time differentiation is shown in Figure 11 and Figure 12.

Figure 10. BLM Q1 Scan without adding Excess of Cu2+.

Figure 11. Excess of Cu2+ and BLM with Molecular Ratio of 50:1 at 3 minutes after
Preparation.
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Figure 12. Excess of Cu2+ and BLM with Molecular Ratio of 50:1 at 15 minutes after
Preparation.

In Figure 11 and Figure 12, it illustrates that the chelation between BLM and Cu
has reversible possibility. At 3 minutes after the sample preparation, almost all BLM had
been transferred into BLM – Cu complex. In the future study, the reaction condition is
able to study, in which the temperature and pH value are changeable in primary.
3.2.3 Mass Spectrometry Q1 Infusion – EDTA Interference
As all plasma samples are treated with EDTA, and EDTA might chelate metal
ions to interfere the result of analysis, it is necessary to research if EDTA functions on
chelation with Cu2+ in this method.
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Figure 13. EDTA and BLM with Molecular Ratio of 50:1.

According to the spectrums in Figure 10 and Figure 13, EDTA is rarely
interfering the result. However, as BLM B2 is more active to chelate Cu than A2, the
signal of BLM B2 – Cu is less than expected presence. There is no BLM B2 present in the
spectrum, so that it is hard to explain whether EDTA is interfering B2.
3.2.4 Mass Spectrometry Q2 Fragmentation – BLM and VCM
To identify the highest signals of fragments for BLM A2 and B2, two different
collision energies were used for each of those fractions. The chosen fragment needs to be
stably present to different collision energy, which indicates its stability and reliability.
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Figure 14. Fragmentation of BLM A2 with Collision Energy of 40 and 46.
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Figure 15. Fragmentation of BLM B2 with Collision Energy of 40 and 48.
According to Figure 14 and Figure 15, the MRM transition of BLM A2 was m/z
739.0 → 515.3, and BLM B2 was m/z 745.0 → 552.0. However, in a following LC-MRM
test, there was a stronger signal of transition of BLM A2 was m/z 739.0 → 708.0.
3.3 HPLC-MS/MS Results
3.3.1 Selection of HPLC Column
As described before, BLM and VCM are polar compounds. Therefore, the best
column for the HPLC analysis is a reverse phase column, and the mostly common choice
would be a C18 column. However, according to a HPLC-MS/MS test (Figure 16), C18
present peaks with obvious tailing issue, and the retentions were around 1 min, which
would easily be indicated as an interference of solvent peak or impurities peak. In this
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method, the final choice was a Synergi 4μ Hydro-RP 80A (50×2.00mm, 4 micron)
column, from which the spectrum present good shapes of the peaks and retentions were
all after 2 minutes (Figure 17).

BLM B2 Has Retention Time at 0.99min

BLM A2 Has Retention Time at ~0.6min

Figure 16. HPLC Chromatogram of BLM A2 and B2 Using a C18 Column.

BLM A2, Retention at 2.46min

VCM,
Retention at
2.22min

BLM B2, Retention at 2.67min

Figure 17. HPLC Chromatogram of BLM A2 and B2 Using a Synergi Hydro-RP C18
Column.
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3.3.2 Methanol Percentage in the Sample
Calibration standards solvent has the ability to affect the retention and elution of
analytes subjected to HPLC. To make the standard preparation simple, the calibration
standards were prepared in methanol and DI-water plus Cu2+ in addition. Previous
research in the literature used 75-90% methanol as the HPLC solvents with their C18
columns.4, 17, 18 However, in this method with 5μL of injection volume, it appeared to be
difficult to retain by using 70% methanol, which is shown in Figure 18. In Figure 18, it
shows that all analytes and internal standard indicate on retention time of 0.87 minutes.
As use of 20% methanol in Figure 19, the problem of retention has been solved, even
when changed to a higher volume injection of 20μL.

Figure 18. HPLC Chromatogram of 200ng/mL BLM in 70% methanol.

30

Figure 19. HPLC Chromatogram of 200ng/mL BLM in 20% methanol.

3.3.3 Mass Chromatograms of Standards Preparation from Table I
The standards were prepared according to Table I, and then protein was
precipitated. 100μL aliquots of the supernatant were ice-dried, and 100μL of 20%
methanol was added to dissolve. The resulting mass chromatograms are shown in Figures
20-26. BLM A2 had a retention time of 2.4 minutes, BLM B2 had a retention time of 2.7
minutes, and VCM had a retention time of 2.2 minutes.

Figure 20. Mass Chromatogram of 1ng/mL of BLM and 40ng/mL of VCM in Plasma.
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Figure 21. Mass Chromatogram of 5ng/mL of BLM and 40ng/mL of VCM in Plasma.

Figure 22. Mass Chromatogram of 10ng/mL of BLM and 40ng/mL of VCM in Plasma.
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Figure 23. Mass Chromatogram of 20ng/mL of BLM and 40ng/mL of VCM in Plasma.

Figure 24. Mass Chromatogram of 50ng/mL of BLM and 40ng/mL of VCM in Plasma.
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Figure 25. Mass Chromatogram of 100ng/mL of BLM and 40ng/mL of VCM in Plasma.

Figure 26. Mass Chromatogram of 200ng/mL of BLM and 40ng/mL of VCM in Plasma.

3.3.4 Calibration Curve of Standards Preparation from Table I
The calibration curves were constructed using seven calibration standards. The
linear calibration range was between 1-200 ng/mL. The calibration curve for rats’ plasma
spiked with BLM and VCM is shown in Figure 27 and 28.
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y = 0.205 x - 0.206
r = 0.9906

Figure 27. Calibration of BLM A2.

y = 0.00778 x + 0.00662
r = 0.9955

Figure 28. Calibration of BLM B2.
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CHAPTER IV
CONCLUSION
Bleomycin quantitative analysis had been developed by spiking excess of Cu2+ to
transfer BLM into BLM-Cu complex, solving the problem of using mixed standards with
exact percentage of each component to quantify clinical samples and eliminating the need
for sophisticated higher resolution instruments that are costly to the lab. Simple
chromatography conditions of solvent buffer was optimized, which makes future study of
BLM metabolism and mechanism achievable.
In the future study of BLM, it is necessary to find the activity of each of BLM A2
and B2 fraction binding to Cu or other metal ions. From the calibration curves that were
made during the entire research, it is obvious that the BLM B2 is more active to bind with
Cu, which was present in their spectrums of mass spectrometry Q1 scan and the quantity
in calibration curves. However, the stability of the complexes would also be worth to
research. Unfortunately, due to sample degradation, the method validation could not be
completed in this work, however sensitivity and selectivity on the samples for the method
development cohort revealed higher sensitivity and selectivity than previously published
methods.
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